5-Year Effectiveness and Safety Data for iTrack™ to be Spotlighted at ESCR S 2021

Fremont, California, 7 October 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report that 60-month results of a retrospective case series featuring the Company’s proprietary iTrack™ canaloplasty microcatheter will be presented at the 39th Congress of the ESCR S, October 8-11, 2021.

In the retrospective case series, German glaucoma surgeons Prof. Norbert Koerber and Dr. Simon Ondrejka evaluated the long-term efficacy and safety of canaloplasty performed with the iTrack™ canaloplasty microcatheter in reducing mean intraocular pressure (IOP) and mean number of glaucoma medications in patients with uncontrolled or controlled open-angle glaucoma (OAG). Most eyes, 23 out of 27, underwent canaloplasty in combination with cataract surgery.

Overall, iTrack™ was found to be an effective option for maintaining a sustained reduction in IOP in OAG patients up to 5 years, reducing from 19.8 ± 5.2 (n=27) at baseline to 15.0 ± 2.6 (n=26), 15.6 ± 3.3 (n=25), 14.7 ± 3.8 (n=21), 14.6 ± 3.0 (n=18) and 14.4 ± 3.3 (n=14) at 12, 24, 36, 48 and 60 months respectively. iTrack™ was also effective in reducing glaucoma medication dependence, with the mean number of medications falling from 1.93 at baseline to 1.21 at 60 months, with 57% of eyes on 1 medication or less at 60 months.

No severe complications occurred either intraoperatively or postoperatively. Importantly, no secondary surgical interventions were required to control IOP in any of the eyes.

Prof. Koerber concluded that, based on the results of this 60-month study, iTrack™ achieves a significant reduction in IOP as compared to baseline, along with a decrease in medication burden. The results also showed that performing canaloplasty with the iTrack™ is a safe procedure associated with a low risk of complications. Importantly, the inclusion of canaloplasty in glaucoma treatment paradigms could reduce the need for medications in patients with controlled glaucoma who are intolerant to, or non-compliant with, medications.
More information is available via the ESCRS website:


“5-Year Efficacy and Safety of iTrack Ab-interno Canaloplasty as a Standalone Procedure and Combined with Cataract Surgery in Primary Open-Angle Glaucoma”

Session title: Glaucoma
Date: 11 October 2021
Time: 12:36 – 12:42pm
Location: Hall 9 (RAI Amsterdam)

All educational content of the ESCRS annual meeting is planned by its program committee, and ESCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

For additional information about canaloplasty, please visit: www.canaloplasty.com
Indication For Use: The iTrack Canaloplasty Microcatheter is indicated for fluid infusion and aspiration during surgery. The iTrack Canaloplasty Microcatheter is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open angle glaucoma. (For full safety information visit https://glaucoma-itrack.com/safety.)